Homologus PRP in the Infiltrative Treatment of Knee Osteoarthritis in Young Athletic Patients

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The study consists of 3 phases (enrollment, infiltrative procedure, and controls): * Identification by specialized orthopedic medical staff belonging to the SC Orthopedic and Trauma Clinic II of the Rizzoli Orthopedic Institute of subjects who meet the study inclusion criteria. Signing of informed consent form and completion of evaluation questionnaires. * infiltrative procedure * Patients will be clinically evaluated before the infiltration procedure and at 1, 3, 6, and 12 months after treatment by trained medical personnel (outcome assessors). Questionnaires will be administered for clinical evaluations before treatment and at these clinical checkups during follow-up. Any adverse events to treatment will also be assessed during follow-up visits. The duration and extent of joint swelling and pain following infiltration will be reported, and any drug therapies taken by the patient will be recorded.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 40
Healthy Volunteers: f
View:

• Patients, both sexes, with symptomatic knee osteoarthritis with:

• Age: 18-40 years;

• Unilateral involvement;

• Signs and symptoms of knee osteoarthritis;

• Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3);

• Ability and consent of patients to actively participate in clinical follow-up;

• Signature of informed consent;

• Pain ≥ 4 on VAS s

Locations
Other Locations
Italy
IRCCS - Istituto ortopedico Rizzoli
RECRUITING
Bologna
Contact Information
Primary
Mirco Lo Presti, MD
mirco.lopresti@ior.it
0516366
Time Frame
Start Date: 2023-10-10
Estimated Completion Date: 2026-09
Participants
Target number of participants: 30
Treatments
Other: infiltrative procedure
Related Therapeutic Areas
Sponsors
Leads: Istituto Ortopedico Rizzoli

This content was sourced from clinicaltrials.gov